Ketone esters show promise for muscle preservation in GLP-1 users
Preclinical findings suggest ketone ester supplementation could mitigate muscle loss associated with GLP-1 receptor agonist (GLP-1RA) therapies like semaglutide, opening new product development avenues.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 26 June 2026
A recent preclinical study highlights the potential of ketone esters to preserve muscle mass and strength in individuals utilising GLP-1 receptor agonist (GLP-1RA) medications, such as semaglutide. The research, conducted on laboratory mice, indicated that co-administering ketone esters alongside semaglutide prevented muscle atrophy and maintained mitochondrial function. This counteracted the typical negative physiological changes associated with GLP-1RA drugs, which often include significant lean mass reduction along with desired fat loss. The study, as reported by NutraIngredients Global, suggests a pathway to developing complementary nutritional strategies that address a key side effect of a rapidly growing pharmaceutical market.
GLP-1RAs are increasingly prescribed for weight management and diabetes, driving a demand for adjunctive therapies that optimise patient outcomes. Maintaining muscle mass is critical for long-term metabolic health and functional capacity. These preclinical results suggest that ketone esters could play a pivotal role in this space, offering a unique selling proposition for supplement brands that can demonstrate efficacy. The intervention did not diminish the fat loss benefits of semaglutide, indicating a targeted protective effect on muscle rather than an interference with the primary mechanism of action of the pharmaceutical.
While the findings are promising, industry experts are unanimous that robust human clinical trials are essential to substantiate these effects. Brand owners and manufacturers evaluating this opportunity must factor in the substantial investment required for clinical validation, regulatory approval, and consumer education regarding the complementary use of supplements with prescription medications. The opportunity lies in positioning ketone ester products as integral to a comprehensive weight management protocol that supports both fat loss and muscle retention, thereby enhancing the overall health trajectory of GLP-1RA users.
What this means for United Kingdom
UK brand owners must immediately assess the commercial viability of formulating ketone ester supplements targeting GLP-1RA users, leveraging a market with an estimated 200,000 semaglutide prescriptions issued in 2024. This requires navigating potential novel food approvals from the FSA and compiling robust safety dossiers. Procurement teams should explore long-term supply agreements for high-purity ketone esters, anticipating increased demand and potential price volatility. Manufacturers capable of producing liquid or gel-based ketone formats may gain competitive advantage, aligning with observed consumer preferences for convenient supplement delivery alongside prescribed medicines. Formulations must clearly differentiate from existing weight management products, emphasising muscle preservation benefits.
What to watch next
- Monitor the initiation and publication of human clinical trials on ketone esters and GLP-1RA co-administration, with initial data points expected within the next 12-18 months.
- Track regulatory guidance from the FSA and EFSA regarding novel food classifications and permitted claims for ketone esters, especially concerning their complementary use with prescription medications, anticipated by late 2027.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.